A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized
study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory
patients with peripheral T-cell lymphoma.